Products - Liver cancers | Topic

Showing 29 products

Date | Sort by Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
24 May 2019
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2021
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2020
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 October 2019
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 August 2021
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
14 December 2022
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
24 April 2024
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement ID3992
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4031]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma TS ID 10503
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence TS ID 10650
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Liver cancers Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 29 products

Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]

Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]

Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940

Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement ID3992

Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4031]

Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma TS ID 10503

Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757

Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence TS ID 10650

Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

Liver cancers Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 29 products

Guidance programme
1 selected